According to GlobalData’s medical device pipeline database, eight Atrial Septal Defect Occluders devices are in various stages of development globally. GlobalData’s report Atrial Septal Defect Occluders provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, seven are in active development, while the remaining three are in an inactive stage of development. There are two products in the early stages of development, and the remaining five are in the late stages of development.
Cardiovascular Devices are used to detect and treat heart and circulatory system related diseases. Atrial Septal Defect Occluders is a self-expandable nitinol mesh that close holes in the heart to prevent the blood flow. Atrial Septal Defect Occluders is delivered using a cardiac catheter and guidewire through a small incision in the groin.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Atrial Septal Defect Occluders pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Atrial Septal Defect Occluders devices. Overall, most of these Atrial Septal Defect Occluders pipeline devices are being developed by private entities.
Key players involved in the active development of Atrial Septal Defect Occluders include Occlutech International, Vascular Closure Systems, atHeart Medical, Carag, Endomimetics, Ension and Lepu Scientech Medical Technology (Shanghai).
For a complete picture of the developmental pipeline for Atrial Septal Defect Occluders devices, buy the report here.